Press Releases

Date Title  
11/22/19 Toca 5 Phase 3 Trial Results Presented at the Society for Neuro-Oncology Annual Meeting
11/12/19 Tocagen Reports Third Quarter 2019 Financial Results and Business Updates
11/08/19 Tocagen Highlights Toca 6 Phase 1b Data at Society for Immunotherapy of Cancer Annual Meeting
11/06/19 Tocagen to Report Third Quarter 2019 Financial Results and Business Updates on Tuesday, November 12
10/03/19 Tocagen Announces Restructuring to Focus on Clinical Development
09/12/19 Tocagen Reports Results of Toca 5 Phase 3 Trial in Recurrent Brain Cancer
08/26/19 Tocagen to Participate in Two Upcoming Investor Conferences
08/08/19 Tocagen Reports Second Quarter 2019 Financial Results and Business Updates
08/01/19 Tocagen to Report Second Quarter 2019 Financial Results and Business Updates on Thursday, August 8
05/30/19 Tocagen to Present at Upcoming Jefferies 2019 Healthcare Conference
05/21/19 Tocagen's Toca 5 Pivotal Phase 3 Clinical Trial in Patients with Recurrent Brain Cancer Continues Without Modification at Planned Interim Analysis
05/07/19 Tocagen Reports First Quarter 2019 Financial and Business Results
04/30/19 Tocagen to Report First Quarter 2019 Financial and Business Results on Tuesday, May 7
04/15/19 Tocagen Appoints Fairooz Kabbinavar, M.D., FACP, as Senior Vice President, Clinical Development
03/27/19 Tocagen to Present Updated Data from Clinical and Preclinical Studies at Two Scientific Conferences
02/27/19 Tocagen Reports Fourth Quarter and Full Year 2018 Financial and Business Results
02/20/19 Tocagen to Report Fourth Quarter and Full Year Financial Results on Wednesday, February 27 and Present at Upcoming SVB Leerink Global Healthcare Conference